Latest Cardiology News

Imricor Medical Systems expands its US market reach with FDA 510(k) clearances for pediatric use of its NorthStar system and Vision-MR Diagnostic Catheter, enabling radiation-free cardiac catheterisations for children.

Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.

CONNEQT Health has lodged an FDA Pre-Submission for SphygmoCor Cloud, aiming to shift its arterial health analytics from hardware to a scalable software platform with broad commercial potential.

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.

Pro Medicus secures a $16 million, 7-year cloud imaging contract with TidalHealth, complementing recent major wins and contract renewals that underscore its growing dominance in North American healthcare IT.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Anteris Technologies has gained U.S. Medicare reimbursement eligibility for its pivotal PARADIGM Trial, clearing a key hurdle for clinical site activation and accelerating its transcatheter heart valve study.

Echo IQ has taken a major step in its US expansion by deploying its AI-powered EchoSolv AS software at Mount Sinai Health System, one of America’s leading cardiovascular centres. This marks a key milestone in integrating AI into routine cardiology workflows at scale.